These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21093415)

  • 1. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
    Zhao X; Li J; Zhuo J; Cai L
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of miR-18a in gastric cancer angiogenesis.
    Zheng Y; Li S; Ding Y; Wang Q; Luo H; Shi Q; Hao Z; Xiao G; Tong S
    Hepatogastroenterology; 2013 Oct; 60(127):1809-13. PubMed ID: 24624454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest.
    Lu X; Qian J; Yu Y; Yang H; Li J
    Oncol Rep; 2009 Sep; 22(3):635-40. PubMed ID: 19639215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma.
    Lee TK; Poon RT; Yuen AP; Ling MT; Wang XH; Wong YC; Guan XY; Man K; Tang ZY; Fan ST
    Clin Cancer Res; 2006 Dec; 12(23):6910-9. PubMed ID: 17145808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis.
    Huang J; Lin Y; Li L; Qing D; Teng XM; Zhang YL; Hu X; Hu Y; Yang P; Han ZG
    Mol Carcinog; 2009 Feb; 48(2):130-40. PubMed ID: 18612997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
    Cheng AS; Chan HL; To KF; Leung WK; Chan KK; Liew CT; Sung JJ
    Int J Oncol; 2004 Apr; 24(4):853-60. PubMed ID: 15010822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
    Bao JJ; Le XF; Wang RY; Yuan J; Wang L; Atkinson EN; LaPushin R; Andreeff M; Fang B; Yu Y; Bast RC
    Cancer Res; 2002 Dec; 62(24):7264-72. PubMed ID: 12499268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
    Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
    Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
    El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
    Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aplasia Ras homologue member I overexpression induces apoptosis through inhibition of survival pathways in human hepatocellular carcinoma cells in culture and in xenograft.
    Pei XH; Yang Z; Liu HX; Qiao SS
    Cell Biol Int; 2011 Oct; 35(10):1019-24. PubMed ID: 21933150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H; Ong R; Soo KC
    Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?
    Moon WS; Rhyu KH; Kang MJ; Lee DG; Yu HC; Yeum JH; Koh GY; Tarnawski AS
    Mod Pathol; 2003 Jun; 16(6):552-7. PubMed ID: 12808060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.